About Bayer Innovation

The Bayer Innovation GmbH

BAYER INNOVATION GmbH (BIG) is part of Bayer’s innovation strategy and complements the innovation activities of the different subgroups in the fields of health care, nutrition and high-quality materials.

Objective of BIG is to identify and develop new growth opportunities, thus preparing entry into new and expanding markets. The fields of activity match Bayer’s overall concept “science for a better life” and take advantage of competences within the subgroups, often in cooperation with external partners such as universities, institutes, start ups or other companies.
Development of innovative solutions across the lines of Bayer’s subgroups and creation of new products and business opportunities are among the strong points of BIG. Currently the focus is on medical technology and the production of plant-made pharmaceuticals.
This way Bayer gains access to attractive future markets. Once these concepts are fully developed they will be committed to commercial integration to appropriate Bayer subgroups, opening up BIG’s resources for new challenges.

Our projects
Plant made Pharmaceuticals
Since January 2006 the Bayer Innovation GmbH is engaged in the field of protein expressions in plants (“plant made pharmaceuticals”). » more

Our projects
Medical Devices
Research in Medical Technology is working on new solutions in domains with high medical and technological demands. » more

News

January 28, 2010
Idiotype vaccination in the treatment of non-Hodgkin’s lymphoma
Bayer starts clinical Phase I study with personalized vaccine from tobacco plants
The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. » more

News Overview